190 related articles for article (PubMed ID: 9781958)
1. Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening.
Tanaka T; Sugimoto T; Sawada T
Cancer; 1998 Oct; 83(8):1626-33. PubMed ID: 9781958
[TBL] [Abstract][Full Text] [Related]
2. trk A gene expression in neuroblastoma. The clinical significance of an immunohistochemical study.
Tanaka T; Hiyama E; Sugimoto T; Sawada T; Tanabe M; Ida N
Cancer; 1995 Sep; 76(6):1086-95. PubMed ID: 8625212
[TBL] [Abstract][Full Text] [Related]
3. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study.
Cohn SL; Look AT; Joshi VV; Holbrook T; Salwen H; Chagnovich D; Chesler L; Rowe ST; Valentine MB; Komuro H
Cancer Res; 1995 Feb; 55(4):721-6. PubMed ID: 7850780
[TBL] [Abstract][Full Text] [Related]
4. Trk mRNA and low affinity nerve growth factor receptor mRNA expression and triploid DNA content in favorable neuroblastoma tumors.
Kogner P; Barbany G; Björk O; Castello MA; Donfrancesco A; Falkmer UG; Hedborg F; Kouvidou H; Persson H; Raschella G
Prog Clin Biol Res; 1994; 385():137-45. PubMed ID: 7972205
[TBL] [Abstract][Full Text] [Related]
5. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis.
Kogner P; Barbany G; Dominici C; Castello MA; Raschellá G; Persson H
Cancer Res; 1993 May; 53(9):2044-50. PubMed ID: 8481906
[TBL] [Abstract][Full Text] [Related]
6. Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favourable neuroblastoma.
Svensson T; Rydén M; Schilling FH; Dominici C; Sehgal R; Ibáñez CF; Kogner P
Eur J Cancer; 1997 Oct; 33(12):2058-63. PubMed ID: 9580079
[TBL] [Abstract][Full Text] [Related]
7. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma.
Nakagawara A; Arima-Nakagawara M; Scavarda NJ; Azar CG; Cantor AB; Brodeur GM
N Engl J Med; 1993 Mar; 328(12):847-54. PubMed ID: 8441429
[TBL] [Abstract][Full Text] [Related]
8. Expression and function of TRK-B and BDNF in human neuroblastomas.
Nakagawara A; Azar CG; Scavarda NJ; Brodeur GM
Mol Cell Biol; 1994 Jan; 14(1):759-67. PubMed ID: 8264643
[TBL] [Abstract][Full Text] [Related]
9. Risk of unfavorable character among neuroblastomas detected through mass screening. The Japanese Infantile Neuroblastoma Cooperative Study.
Tanaka T; Matsumura T; Iehara T; Sawada T
Med Pediatr Oncol; 2000 Dec; 35(6):705-7. PubMed ID: 11107151
[TBL] [Abstract][Full Text] [Related]
10. Activation of TRK genes in Ewing's sarcoma. Trk A receptor expression linked to neural differentiation.
Nogueira E; Navarro S; Pellín A; Llombart-Bosch A
Diagn Mol Pathol; 1997 Feb; 6(1):10-6. PubMed ID: 9028732
[TBL] [Abstract][Full Text] [Related]
11. Unfavorable DNA ploidy and Ha-ras p21 findings in neuroblastomas detected through mass screening.
Kusafuka T; Nagahara N; Oue T; Imura K; Nakamura T; Kobayashi Y; Komoto Y; Fukuzawa M; Okada A; Nakayama M
Cancer; 1995 Aug; 76(4):695-9. PubMed ID: 8625168
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathology of human neuroblastomas.
Brodeur GM
Semin Diagn Pathol; 1994 May; 11(2):118-25. PubMed ID: 7809505
[TBL] [Abstract][Full Text] [Related]
13. Identification of therapy-sensitive and therapy-resistant neuroblastoma subtypes in stages III, IVs and IV.
Kyo Y; Tanaka T; Hayashi K; Iehara T; Kaneko M; Hosoi H; Sugimoto T; Hamasaki M; Kobayashi M; Sawada T
Cancer Lett; 2011 Jul; 306(1):27-33. PubMed ID: 21486686
[TBL] [Abstract][Full Text] [Related]
14. Expression of TrkA, TrkB and TrkC in human neuroblastomas.
Brodeur GM; Nakagawara A; Yamashiro DJ; Ikegaki N; Liu XG; Azar CG; Lee CP; Evans AE
J Neurooncol; 1997 Jan; 31(1-2):49-55. PubMed ID: 9049830
[TBL] [Abstract][Full Text] [Related]
15. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas.
Suzuki T; Bogenmann E; Shimada H; Stram D; Seeger RC
J Natl Cancer Inst; 1993 Mar; 85(5):377-84. PubMed ID: 8433391
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of molecular markers in neuroblastoma: results from a single institution.
Gallego S; Parareda A; Munell F; Sanchez de Toledo J; Reventos J
Oncol Rep; 1999; 6(4):891-6. PubMed ID: 10373677
[TBL] [Abstract][Full Text] [Related]
17. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas.
Nakagawara A; Arima M; Azar CG; Scavarda NJ; Brodeur GM
Cancer Res; 1992 Mar; 52(5):1364-8. PubMed ID: 1737399
[TBL] [Abstract][Full Text] [Related]
18. Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas.
Tang XX; Evans AE; Zhao H; Cnaan A; Brodeur GM; Ikegaki N
Med Pediatr Oncol; 2001 Jan; 36(1):80-2. PubMed ID: 11464911
[TBL] [Abstract][Full Text] [Related]
19. Neuronal src and trk a protooncogene expression in neuroblastomas and patient prognosis.
Matsunaga T; Shirasawa H; Enomoto H; Yoshida H; Iwai J; Tanabe M; Kawamura K; Etoh T; Ohnuma N
Int J Cancer; 1998 Jun; 79(3):226-31. PubMed ID: 9645342
[TBL] [Abstract][Full Text] [Related]
20. Diversity in neuroblastomas and discrimination of the risk to progress.
Tanaka T; Iehara T; Sugimoto T; Hamasaki M; Teramukai S; Tsuchida Y; Kaneko M; Sawada T
Cancer Lett; 2005 Oct; 228(1-2):267-70. PubMed ID: 15913885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
